secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-05-14T12:15:18+00:00
Accession:  0001193125-26-222892
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026
--------------------------------------------------------------------------------

- Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.
- Cash and equivalents $194.8M as of March 31, 2026, expected to fund operations into Q1 2028.
- Plans to submit BLA for aglatimagene (CAN-2409) in localized prostate cancer in Q4 2026.
- Extended follow-up from Phase 2a NSCLC trial shows 50% of patients survived >24 months; Phase 3 NSCLC trial to start June 2026.
- Announced commercial partnership with EVERSANA and $100M royalty funding agreement with RTW for potential launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/0001193125-26-222892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer